Immune Disorders

Imbruvica Approved for the Treatment of Chronic GVHD

By August 02, 2017

This marks the first FDA-approved treatment for cGVHD.

Benlysta FDA-Approved as New Self-Injectable Formulation

By July 21, 2017

The FDA approval was supported by data from the BLISS-SC Phase 3 study (n>800) in patients with active SLE.

Giant Cell Arteritis Treatment Gets FDA Approval

By May 22, 2017

In the study, Actemra given weekly and bi-weekly combined with a 6-month glucocorticoid regimen, more effectively sustained remission through Week 52 than placebo combined with a 26-week steroid taper and a 52-week steroid taper.

Plant Found to Harbor Drug-Resistant Fungal Pathogen

By May 18, 2017

Results showed that 5 of the 6 bulb packages tested positive for triazole-resistant A. fumigatus.

Progress Made in Possible First Treatment for Lymphedema

May 11, 2017

Based on the lab findings, a clinical trial testing bestatin against lymphedema is underway, Dr. Stanley Rockson lead author of the research.

Updated Review of Discoid Lupus Erythematosus Treatments

By May 09, 2017

For each of the five studies, researchers found a potential for bias through conducting a 'Risk of bias' assessment; none of the trials were deemed 'high quality'

Insulin Autoimmune Syndrome Treated with Rituximab

May 05, 2017

Following treatment with rituximab, decreases seen in total insulin, anti-insulin antibody concentration

Powder Form of Ilaris Permanently Discontinued

By April 28, 2017

Ilaris for Injection will be replaced by Ilaris Injection (solution) for subcutaneous use.

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

FDA Expands Thymoglobulin Use in Renal Transplant Patients

By April 24, 2017

Thymoglobulin was originally approved for the treatment of renal transplant acute rejection in 1998. It is available as single-use 10mL vials containing 25mg of anti-thymocyte globulin as a lyophilized powder.

Tissue-Based Tx Granted Breakthrough Status for Complete DiGeorge Syndrome

By April 19, 2017

The FDA has granted Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations for the investigational tissue-based therapy, RVT-802 (Enzyvant), for the treatment of complete DiGeorge Syndrome (cDGS).

FDA to Review Fostamatinib for Chronic, Persistent ITP

By April 18, 2017

Rigel announced its submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenic purpura (ITP).

Imbruvica Under Review for Graft-Versus-Host-Disease

By April 05, 2017

Imbruvica is a first-in-class, oral Bruton's tyrosine kinase (BTK) inhibitor.

Novel Budesonide Prep May Treat Rare GI Disorder

March 28, 2017

A trial involving 93 eosinophilic esophagitis patients aged 11 to 40 years with dysphagia were randomly allocated to receive either budesonide oral suspension or placebo twice daily.

Rituxan Gets Breakthrough Therapy Status for Rare Autoimmune Skin Disorder

By March 24, 2017

Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

Holy Basil: Health Benefits of 'The Elixir of Life'

February 22, 2017

Holy basil is not recommended for pregnant or nursing mothers or young children. It should also be used with caution in patients with diabetes.

Psoriasis Treatment Linked to Drug-Induced Lupus Erythematosus

February 21, 2017

Patient with psoriasis developed muscle pain with paresthesia, ANA titer elevation with adalimumab

Gammaplex 10% Gets FDA Approval

By February 07, 2017

Bio Products Laboratory announced that the Food and Drug Administration (FDA) has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults.

Researchers Grow First Human-Pig Chimeras

By January 27, 2017

Researchers have successfully grown human stem cells in pig embryos, setting in motion a path of research which could lead to human organs being grown in animals for the purpose of transplantation.

Tocilizumab Gets Priority Review for Treatment of Giant Cell Arteritis

By January 24, 2017

Genentech has announced that the Food and Drug Administration (FDA) has accepted the company's Supplmental New Drug Application (sBLA) for Actemra (tocilizumab) to treat giant cell arteritis (GCA).

Islet Autoimmunity Measured With Non- and Hydrolyzed Cow's Milk

January 20, 2017

Use of hydrolyzed cow's milk-based formula introduced during the first seven days is associated with increased risk of islet autoimmunity in infants at increased risk of type 1 diabetes (T1D), according to a study published online in Diabetes Care.

Just 20 Minutes of Exercise Shows Surprising Benefits

January 19, 2017

Just 20 minutes of moderate exercise may reduce inflammation in the body, according to research published online recently in Brain, Behavior, and Immunity.

Masitinib Examined in Severely Symptomatic Indolent Systemic Mastocytosis

By January 06, 2017

Lortholary, O, Chandesris, MO, Livideanu CB, et al. "Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study."

Sustained Disease Control Seen With Long-Term Belimumab in SLE

By November 16, 2016

Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.

Cuvitru Now Available for Primary Immunodeficiency

By November 16, 2016

Shire announced the launch of Cuvitru (immune globulin subcutaneous [human], 20% solution) indicated as replacement therapy for primary humoral immunodeficiency (PI) in patients aged ≥2 years.

Tocilizumab Superior to Steroids Alone for Giant Cell Arteritis Remission

By November 15, 2016

Positive data was presented for Actemra (tocilizumab) therapy in patients with giant cell arteritis (GCA).

Study Examines Rubella Persistence Post-Vaccine in Immunodeficient Patients

By November 10, 2016

Some patients with primary immunodeficiency disorders may be at risk for rubella virus infection and possible serious skin inflammation after receiving the rubella vaccine, a study published in the Journal of Allergy and Clinical Immunology has found.

Classwide Update for PPIs Warns of Cutaneous, Systemic Lupus Erythematosus

By October 28, 2016

PPIs are indicated for the treatment of erosive esophagitis and gastroesophageal reflux disease (GERD).

Actemra Designated Breakthrough Therapy for Giant Cell Arteritis

By October 05, 2016

Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition that is more likely to affect women than men.

CDC: Better Flu Vaccine Coverage for Healthcare Workers Needed

October 03, 2016

Vaccination protects both workers and patients